French health reform bill to address drug shortages, clinical trials
This article was originally published in Scrip
The French parliament is preparing to examine a bill reforming the healthcare system as part of the national health strategy launched by the government in 2013. While the main thrust of the draft "Health Law" is to iron out inequalities and inefficiencies in the healthcare system, it includes proposals to avoid shortages of high therapeutic value medicines and to bring French legislation into line with the new EU Clinical Trials Regulation.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.